Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi
Open Access
- 1 March 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (3), 917-921
- https://doi.org/10.1128/aac.50.3.917-921.2006
Abstract
We have compared the activities of posaconazole and other currently available antifungal agents against a collection of 3,378 clinical isolates of yeasts and filamentous fungi. A total of 1,997 clinical isolates of Candida spp., 359 of other yeast species, 697 strains of Aspergillus spp., and 325 nondermatophyte non- Aspergillus spp. were included. The average geometric means of the MICs of agents that were tested against Candida spp. were 0.23 μg/ml for amphotericin B, 0.29 μg/ml for flucytosine, 0.97 μg/ml for fluconazole, 0.07 μg/ml for itraconazole, 0.04 μg/ml for voriconazole, 0.15 μg/ml for caspofungin, and 0.03 μg/ml for posaconazole. Voriconazole and posaconazole were active in vitro against the majority of isolates, with resistance to fluconazole and itraconazole, and against Cryptococcus neoformans and other Basidiomycota yeasts. Posaconazole was the most active of antifungal agents tested against Aspergillus spp., with an average geometric mean of 0.10 μg/ml. It was active against Paecilomyces spp., Penicillium spp., Scedosporium apiospermum , and some black fungi, such as Alternaria spp. Multiresistant filamentous fungi, such as Scedosporium prolificans , Scopulariopsis brevicaulis , and Fusarium solani , were also resistant to voriconazole, caspofungin, and posaconazole. Amphotericin B and posaconazole were found to be active against most of the Mucorales strains tested. Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species.Keywords
This publication has 29 references indexed in Scilit:
- Analysis of the Influence of Tween Concentration, Inoculum Size, Assay Medium, and Reading Time on Susceptibility Testing of Aspergillus sppJournal of Clinical Microbiology, 2005
- Oral Bioavailability of Posaconazole in Fasted Healthy SubjectsClinical Pharmacokinetics, 2005
- PosaconazoleDrugs, 2005
- Method for the determination of minimum inhibitory concentration (MIC) by broth dilution of fermentative yeastsClinical Microbiology & Infection, 2003
- Experimental Pulmonary Aspergillosis Due toAspergillus terreus:Pathogenesis and Treatment of an Emerging Fungal Pathogen Resistant to Amphotericin BThe Journal of Infectious Diseases, 2003
- Scopulariopsis brevicaulis, a Fungal Pathogen Resistant to Broad-Spectrum Antifungal AgentsAntimicrobial Agents and Chemotherapy, 2003
- Progressive Cutaneous Hyalohyphomycosis Due toPaecilomyces lilacinus:Rapid Response to Treatment with Caspofungin and ItraconazoleClinical Infectious Diseases, 2002
- Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000Antimicrobial Agents and Chemotherapy, 2002
- In Vitro Antifungal Susceptibilities of Trichosporon SpeciesAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformansAntimicrobial Agents and Chemotherapy, 2001